|
||||||||||||||||
|
||||||||||||||||
|
||||||||||||||||
|
||||||||||||||||
|
||||||||||||||||
BMI's Executive Summary[TOP] While larger than its Baltic counterparts in terms of value, the Lithuanian pharmaceutical market remains one of the smallest in the Central and Eastern European (CEE) region. While its' recent growth has been strong – 14% year-on-year (y-o-y) for the three months February through April 2007 – according to distributor Tamro, funding pressures and out-of-pocket spending on drugs, limited by patient purchasing power leads BMI to forecasts for the coming five years annual growth at single-digit figures. Market growth is also contingent on the country's fractious parliament and current weak government managing to steward the fast-growing economy or fresh elections yielding more workable arrangements before the next round of scheduled parliament polls in October 2008. In the meantime, the country's creaking public services – in particular healthcare – require urgent attention despite the attempts of successive governments to develop a modern primary sector, with doctors providing a gatekeeper function to specialists. While the president appears committed to reducing corruption, power struggles and appeals to populism are blamed for preventing movement on badly needed economic and social reforms. However, although the fractious political scene threatens to derail the much-needed reforms, the new multiparty governing coalition has put forward a platform based on investment in social services. In the adjusted BMI 's Business Environment Rankings for the 15 major markets of Central & Eastern Europe (CEE), Lithuania is ranked joint twelfth, alongside Croatia. While Lithuania's strong economic growth and surging levels of consumer spending are stimulating pharmaceutical market growth, economic and political risks remain a cause for concern. Lithuania was expected to fully harmonise national with EU pharmaceutical legislation by the end of 2007, which should further facilitate market entry for foreign players. The country's drug manufacturing sector is small and export-oriented, given the constraints of the local market. Given the trend of industry consolidation following the European Union (EU) membership, even the larger players in the country could potentially emerge as take-over targets for key global players in the medium to longer term. Multinationals will continue to supply the bulk of patented medicines through imports, although no plans are being made for establishing local manufacturing facilities. The strong local demand for generics is fuelling the expansion of large CEE players in the Lithuanian market. |
||||||||||||||||
|
||||||||||||||||
Contents[TOP] Chapter 1 - Executive SummaryLithuania Pharmaceuticals & Healthcare Industry SWOT Chapter 2 - Lithuania: Business Environment RankingTable: Central & Eastern Europe Pharmaceuticals Business Environment Ranking Business Environment Ranking Economics - Long-Term Risk Politics - Long-Term Risk Regulatory Barriers Domestic Sector Threat Market Growth Potential Market Size Ranking Chapter 3 - Lithuania: Market SummaryChapter 4 - Regulatory RegimeIntellectual Property Developments Pricing & Reimbursement Issues Healthcare Sector Developments Chapter 5 - Industry Forecast ScenarioOverall Market Forecast Table: Lithuania Drug Market Forecast Indicator Key Growth Factors - Industry Table: Lithuania Healthcare Expenditure Forecast Indicators Key Growth Factors - Macroeconomic Table: Indicators Of Economic Activity Prescription Market Forecast Table: Lithuania Prescription Drug Market Forecast Indicators OTC Market Forecast Table: Lithuania OTC Market Forecast Indicators Generics Market Forecast Table: Lithuania Generics Market Forecast Indicators Export/Import Forecasts Table: Lithuania Pharmaceutical Export & Import Forecast Indicators Other Healthcare Data Forecasts Table: Other Healthcare Data Forecasts Risks To BMI's Forecast Scenario Chapter 6 - Competitive LandscapeTable: Leading Pharmaceutical Manufacturers in Lithuania Chapter 7 - Company ProfilesValentis Sanitas Chapter 8 - BMI Forecast ModellingHow We Generate Our Industry Forecasts Technical Process Pharmaceutical Industry Sources Chapter 9 - Appendix: Regional Demographic DataWages (ave labour force per annum), US$ PPP Population Household Spending Per Capita, US$ Private Consumption Per Capita, US$ PPP Market Size, GDP, US$bn Chapter 10 - Country Snapshot: Lithuania Demographic DataSection 1: Population Table: Demographic Indicators (2005) Table: Rural/Urban Breakdown Section 2: Education & Healthcare Table: Education Table: Healthcare: Vital Statistics Table: Healthcare: Expenditure Section 3: Labour Market And Spending Power Table: Employment Indicators Table: Consumption And Stratification Table: Wages Per Year
|
||||||||||||||||
|
||||||||||||||||
Competitive Landscape for Europe Pharmaceuticals and Healthcare: Sample of Companies Ranked[TOP] Cross-border analysis of regulatory systems comparing the patenting environment, summarising regional pricing and reimbursement factors and monitoring the growth of the Pharmaceuticals sector across the region. Company SWOTs cover leading multinational and national drug companies operating in each market.
|
||||||||||||||||
Network of European Pharmaceutical & Healthcare Sources[TOP] BMI's Pharmaceuticals & Healthcare Reports are based on an extensive network of multilateral organisations, government departments, pharmaceutical & healthcare industry associations, chambers of commerce and company reports. Information sources include:
|
||||||||||||||||
|
||||||||||||||||
|
||||||||||||||||
|
||||||||||||||||